373 related articles for article (PubMed ID: 9261127)
1. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor.
Montrose-Rafizadeh C; Yang H; Rodgers BD; Beday A; Pritchette LA; Eng J
J Biol Chem; 1997 Aug; 272(34):21201-6. PubMed ID: 9261127
[TBL] [Abstract][Full Text] [Related]
2. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
[TBL] [Abstract][Full Text] [Related]
3. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39).
Fehmann HC; Jiang J; Schweinfurth J; Wheeler MB; Boyd AE; Göke B
Peptides; 1994; 15(3):453-6. PubMed ID: 7937318
[TBL] [Abstract][Full Text] [Related]
4. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1.
López de Maturana R; Willshaw A; Kuntzsch A; Rudolph R; Donnelly D
J Biol Chem; 2003 Mar; 278(12):10195-200. PubMed ID: 12524435
[TBL] [Abstract][Full Text] [Related]
5. Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro.
Swedberg JE; Schroeder CI; Mitchell JM; Fairlie DP; Edmonds DJ; Griffith DA; Ruggeri RB; Derksen DR; Loria PM; Price DA; Liras S; Craik DJ
J Biol Chem; 2016 Jul; 291(30):15778-87. PubMed ID: 27226591
[TBL] [Abstract][Full Text] [Related]
6. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
Coopman K; Wallis R; Robb G; Brown AJ; Wilkinson GF; Timms D; Willars GB
Mol Endocrinol; 2011 Oct; 25(10):1804-18. PubMed ID: 21868452
[TBL] [Abstract][Full Text] [Related]
7. Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2.
Schepp W; Schmidtler J; Riedel T; Dehne K; Schusdziarra V; Holst JJ; Eng J; Raufman JP; Classen M
Eur J Pharmacol; 1994 Oct; 269(2):183-91. PubMed ID: 7851494
[TBL] [Abstract][Full Text] [Related]
8. The amino terminal domain of the glucagon-like peptide-1 receptor is a critical determinant of subtype specificity.
Graziano MP; Hey PJ; Strader CD
Recept Channels; 1996; 4(1):9-17. PubMed ID: 8723643
[TBL] [Abstract][Full Text] [Related]
9. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes.
Montrose-Rafizadeh C; Yang H; Wang Y; Roth J; Montrose MH; Adams LG
J Cell Physiol; 1997 Sep; 172(3):275-83. PubMed ID: 9284947
[TBL] [Abstract][Full Text] [Related]
10. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.
Al-Sabah S; Donnelly D
Br J Pharmacol; 2003 Sep; 140(2):339-46. PubMed ID: 12970080
[TBL] [Abstract][Full Text] [Related]
11. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
12. Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues.
López de Maturana R; Treece-Birch J; Abidi F; Findlay JB; Donnelly D
Protein Pept Lett; 2004 Feb; 11(1):15-22. PubMed ID: 14965274
[TBL] [Abstract][Full Text] [Related]
13. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues.
Pohl M; Wank SA
J Biol Chem; 1998 Apr; 273(16):9778-84. PubMed ID: 9545315
[TBL] [Abstract][Full Text] [Related]
15. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor.
Thorens B; Porret A; Bühler L; Deng SP; Morel P; Widmann C
Diabetes; 1993 Nov; 42(11):1678-82. PubMed ID: 8405712
[TBL] [Abstract][Full Text] [Related]
16. The primary ligand-binding interaction at the GLP-1 receptor is via the putative helix of the peptide agonists.
Al-Sabah S; Donnelly D
Protein Pept Lett; 2004 Feb; 11(1):9-14. PubMed ID: 14965273
[TBL] [Abstract][Full Text] [Related]
17. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
Baggio LL; Huang Q; Brown TJ; Drucker DJ
Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
[TBL] [Abstract][Full Text] [Related]
18. Fluorescein-Trp25-exendin-4, a biologically active fluorescent probe for the human GLP-1 receptor.
Chicchi GG; Cascieri MA; Graziano MP; Calahan T; Tota MR
Peptides; 1997; 18(2):319-21. PubMed ID: 9149306
[TBL] [Abstract][Full Text] [Related]
19. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4.
Raufman JP; Singh L; Singh G; Eng J
J Biol Chem; 1992 Oct; 267(30):21432-7. PubMed ID: 1328231
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
